Why Parkinson's disease?

Parkinson’s disease is the fastest growing neurological condition in the world but treatments for the disease haven’t progressed for over 50 years. Our world-class researchers are progressing treatments to combat the disease.

Parkinson's patient story

Meet Andrew Myers

“If the disease could be delayed in its progression, it would give me more time to do the things I hoped I’d be doing at this stage in life.”

Andrew
Parkinson's Patient and Sheffield Graduate

Hear about Andrew's experience in his own words

Our researchers

Parkinson's disease Q&A

Professor Oliver Bandmann explains our work into Parkinson's, and answers your questions about the disease.

PhD student Toby Burgess (far right)
PhD student Toby Burgess (far right) with supervisor Dr Heather Mortiboys (2nd from right)

The next generation of Parkinson's experts

Toby Burgess is a First Year PhD Student, studying grouping Parkinson's patients into classes based on the underlying cause behind their disease. The results of this will hopefully lead to more tailored treatments.

The next generation of Parkinson's experts at Sheffield

Bright Minds - Neuroscience

Neuroscience researchers Dr Simon Bell and Dr Tom Payne share bite-sized talks about their research into Alzheimer's Disease and Parkinson's Disease.

Explaining Parkinson's disease

By gaining a better understanding of Parkinson's, scientists in our Neuroscience Institute are working towards potentially life-changing treatments to slow it down and one day halt it in its tracks.

Neuroscience Institute

Our research and impact so far

Graphic showing brain and drug discovery research

Sheffield scientists awarded £1.2 million to design Parkinson’s drug

Scientists from the University of Sheffield have been awarded £1.2 million to develop a drug to protect dopamine-producing brain cells and slow down the progression of Parkinson’s disease.

Read the full story

Scientist running drug screening in lab

New partnership to develop drug targets for the treatment of Parkinson’s disease

Our researchers are collaborating with Verge Genomics to accelerate the validation of novel drug targets and the screening of new drug compounds for the treatment of Parkinson’s disease.

Read the full story

Old and newly made dopamine-producing nerve cells in the zebrafish brain
Old and newly made dopamine-producing nerve cells in the zebrafish brain

Parkinson's gene may impair how new neurons are made throughout our lifetime

A gene defect linked to Parkinson’s disease may not only cause the early death of neurons, but also impair the process that generates neurons in the brain throughout our lifetime, a new study has revealed.

Read the full story

Related information

The Big Week hub
The Big Week Fundraise-athon
The Big Week moving challenge